ESR1 and breast cancer: In the UAE, a short letter to the editor reported an overall incidence of estrogen-receptor-positive (ER+), progesterone-receptor-positive (PR+), HER2+, and TN tumors of 59.3%, 51.0%, 39.1%, and 20.8%, respectively, among the 192 patients diagnosed with BC between April 2008 and May 2009 [38].